Its moderate IL-15R affinity and lower potency compared to IL-15 superagonists and even rhIL-15 is considered advantageous, as high affinity IL-15R binding would have negatively interfered with TA-MUC1-mediated tumor accumulation due to fast clearance by a cytokine sink [11]. The gene discussed is MUC1; the disease is neoplasm.